Erste Asset Management GmbH Buys 10,000 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Erste Asset Management GmbH increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 60.6% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 26,510 shares of the biopharmaceutical company’s stock after buying an additional 10,000 shares during the quarter. Erste Asset Management GmbH’s holdings in Alnylam Pharmaceuticals were worth $6,309,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Huntington National Bank lifted its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares in the last quarter. Larson Financial Group LLC lifted its holdings in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $33,000. True Wealth Design LLC increased its stake in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares during the last quarter. Finally, OFI Invest Asset Management bought a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $35,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $241.75 on Friday. The stock’s fifty day moving average is $254.86 and its two-hundred day moving average is $260.57. The firm has a market capitalization of $31.30 billion, a P/E ratio of -111.41 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a research report on Tuesday. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $310.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Sanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Finally, Piper Sandler restated an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $304.26.

Insider Activity at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.